U.S. Hormone Replacement Therapy Market

U.S. Hormone Replacement Therapy Market by Products (Estrogen & Progesterone Replacement Therapy, Replacement Therapy, Thyroid Hormone Replacement Therapy, Testosterone Replacement, Therapy, Parathyroid Hormone, and Human Growth Hormone), Routes Of Administration (Oral, Parenteral, Transdermal, and Others), Disease Types (Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, and Hypoparathyroidism), and Country - Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-2023
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 182
  • Format:
  • Pub. Date: Upcoming
  • Share:

The U.S. hormone replacement therapy market size is projected to register a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing number of incidences due to hormonal imbalance disorders and rising neonates suffering from these diseases.

U.S. Hormone Replacement Therapy Market summary

Hormone replacement therapy includes a range of diagnosis and treatment of the health conditions for women having low hormone levels. Women, having this disorder, usually takes progestin and often estrogen to combat the symptoms aroused by low hormone levels. As per a study released by the University of Wisconsin Hospitals and Clinics Authority, the chances of hypogonadism rises with age and over 11.0% of men with the age of 50 years and 18.0% of men with the age of 60 years are likely to suffer from hypogonadism in the U.S. In the country, it is also reported that most of these cases remains undertreated and underdiagnosed. American Thyroid Association advised that over 11.0% of the U.S. population is estimated to experience thyroid disorder in their life span and approximately 19.0 million U.S. citizens have some form of thyroid disease.

One in every 4000 neonates are likely to experience congenital hypothyroidism and left unattended, which lead to result in the severe consequence such as mental retardation, according to the Centers for Disease Control and Prevention (CDC). The main players are focusing in the development of innovative products with various formulation to increase acceptance and compliance among patients, which is further expected to boost market growth.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing incidences of different hormonal imbalance disorders and rising geriatric population experiencing these diseases are expected to fuel market growth.
  • Increasing awareness about such diseases and wide adoption of the therapy among patients are key factors boosting the growth of the market.
  • High incidences of congenital disorder in newborns and increasing incidences of vasomotor symptom and vaginal atrophy are expected to drive the market.
  • Adverse reactions and risk of cancer in women due to drugs found in estrogen therapy is expected to restrain the market growth.
  • High cost of treatment of hormone replacement therapy is a key challenge that can hinder the market revenue.

Scope of the Report

The report on the U.S. hormone replacement therapy market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

U.S. Hormone Replacement Therapy Market - Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Products (Estrogen & Progesterone Replacement Therapy, Replacement Therapy, Thyroid Hormone Replacement Therapy, Testosterone Replacement, Therapy, Parathyroid Hormone, and Human Growth Hormone), Routes Of Administration (Oral, Parenteral, Transdermal, and Others), and Disease Types (Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, and Hypoparathyroidism),

Country

The United States

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Abbott; Pfizer, Inc.; AbbVie Inc; Mylan N.V.; Merck & Co. Inc.; Novo Nordisk A/S; Bayer Cropscience Ltd.; Eli Lilly and Co.; and F. Hoffmann La Roche AG

Market Segment Insights

Estrogen & progesterone replacement therapy segment is expected to grow at a rapid pace

Based on products, the U.S. hormone replacement therapy market is divided into estrogen & progesterone replacement therapy, replacement therapy, thyroid hormone replacement therapy, testosterone replacement, therapy, parathyroid hormone, and human growth hormone. The estrogen & progesterone replacement therapy segment is expected to grow at a rapid pace in the coming years owing to introduction of innovative products and technology. However, the parathyroid hormone segment is anticipated to expand at a substantial growth rate during the forecast period due to the approval of U.S. Food and Drug Administration for the use of recombinant human parathyroid hormone, which is for the treatment of adults with chronic diseases.

Oral segment is projected to account for a key market share

On the basis of route of administration, the market is segregated into oral, parenteral, transdermal, and others. The oral segment is projected to account for a key share of the market during the forecast period owing to introduction of oral testosterone products. Meanwhile, the parenteral segment is anticipated to expand at a considerable CAGR during the forecast period due to the launch of long-acting growth hormones and pen-based versions to contribute to accurate dosing and reduced adverse effects from chronic diseases.

Menopause segment is expected to expand at a robust growth rate

Based on disease types, the U.S. hormone replacement therapy market is divided into menopause, hypothyroidism, male hypogonadism, growth hormone deficiency, and hypoparathyroidism. The menopause segment is expected to expand at a robust growth rate during the forecast period owing to rise in the number of menopausal women and rise in the number of vasomotor symptoms incidences. On the other hand, the hypoparathyroidism segment is anticipated to constitute a key market share during the forecast period due to increase in the number of innovative products and novel treatments.

 

Segments

Segments Covered in the Report
The U.S. hormone replacement therapy market has been segmented on the basis of
Products

  • Estrogen & Progesterone Replacement Therapy
  • Human Growth Hormone (HGH) Replacement Therapy
  • Thyroid Hormone Replacement Therapy
  • Testosterone Replacement Therapy
  • Parathyroid Hormone

Routes of Administration

  • Oral
  • Parenteral
  • Transdermal
  • Others

Disease Types

  • Menopause
  • Hypothyroidism
  • Male Hypogonadism
  • Growth Hormone Deficiency
  • Hypoparathyroidism

Country

  • The United States

Key Players

  • Abbott
  • Pfizer, Inc.
  • AbbVie Inc
  • Mylan N.V.
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Bayer Cropscience Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche AG

 

Competitive Landscape

Key players competing in the U.S. hormone replacement therapy market are Abbott; Pfizer, Inc.; AbbVie Inc; Mylan N.V.; Merck & Co. Inc.; Novo Nordisk A/S; Bayer Cropscience Ltd.; Eli Lilly and co.; F. Hoffmann La Roche AG. These main players are focusing in the development of innovative products with various formulation to increase patient acceptance and compliance, which is further expected to lead the market growth. Novo Nordisk A/S announced that it got the U.S. FDA acceptance for its products’ Biologics License Application for Sogroya in August 2020.

U.S. Hormone Replacement Therapy Market keyplayers

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hormone Replacement Therapy Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Hormone Replacement Therapy Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Hormone Replacement Therapy Market - Supply Chain
  4.5. Global Hormone Replacement Therapy Market Forecast
     4.5.1. Hormone Replacement Therapy Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Hormone Replacement Therapy Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Hormone Replacement Therapy Market Absolute $ Opportunity
5. Global Hormone Replacement Therapy Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Hormone Replacement Therapy Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Hormone Replacement Therapy Demand Share Forecast, 2019-2026
6. North America Hormone Replacement Therapy Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Hormone Replacement Therapy Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Hormone Replacement Therapy Demand Share Forecast, 2019-2026
7. Latin America Hormone Replacement Therapy Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Hormone Replacement Therapy Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Hormone Replacement Therapy Demand Share Forecast, 2019-2026
8. Europe Hormone Replacement Therapy Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Hormone Replacement Therapy Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Hormone Replacement Therapy Demand Share Forecast, 2019-2026
9. Asia Pacific Hormone Replacement Therapy Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Hormone Replacement Therapy Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Hormone Replacement Therapy Demand Share Forecast, 2019-2026
10. Middle East & Africa Hormone Replacement Therapy Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Hormone Replacement Therapy Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Hormone Replacement Therapy Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Hormone Replacement Therapy Market: Market Share Analysis
  11.2. Hormone Replacement Therapy Distributors and Customers
  11.3. Hormone Replacement Therapy Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Abbott
     11.4.2. Pfizer, Inc.
     11.4.3. AbbVie Inc
     11.4.4. Mylan N.V.
     11.4.5. Merck & Co. Inc.
     11.4.6. Novo Nordisk A/S
     11.4.7. Bayer Cropscience Ltd.
     11.4.8. Eli Lilly and Co.

Segments Covered in the Report
The U.S. hormone replacement therapy market has been segmented on the basis of
Products

  • Estrogen & Progesterone Replacement Therapy
  • Human Growth Hormone (HGH) Replacement Therapy
  • Thyroid Hormone Replacement Therapy
  • Testosterone Replacement Therapy
  • Parathyroid Hormone

Routes of Administration

  • Oral
  • Parenteral
  • Transdermal
  • Others

Disease Types

  • Menopause
  • Hypothyroidism
  • Male Hypogonadism
  • Growth Hormone Deficiency
  • Hypoparathyroidism

Country

  • The United States

Key Players

  • Abbott
  • Pfizer, Inc.
  • AbbVie Inc
  • Mylan N.V.
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Bayer Cropscience Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche AG

 

Key players competing in the U.S. hormone replacement therapy market are Abbott; Pfizer, Inc.; AbbVie Inc; Mylan N.V.; Merck & Co. Inc.; Novo Nordisk A/S; Bayer Cropscience Ltd.; Eli Lilly and co.; F. Hoffmann La Roche AG. These main players are focusing in the development of innovative products with various formulation to increase patient acceptance and compliance, which is further expected to lead the market growth. Novo Nordisk A/S announced that it got the U.S. FDA acceptance for its products’ Biologics License Application for Sogroya in August 2020.

U.S. Hormone Replacement Therapy Market keyplayers

Buy Report